Seltoplasmid Plus Revascularization for Diabetic Infrapopliteal Chronic Limb-Threatening Ischemia

A phase 4 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 180 participants.

Also called NCT07827521

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; single masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 180 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT07827521
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Not yet recruiting (from the registry)

Technical summary

Registry record NCT07827521. Randomized; single masking; primary purpose treatment. Start 2026-10-20 (anticipated); primary completion 2028-10-01 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Seltoplasmid Plus Revascularization for Diabetic Infrapopliteal Chronic Limb-Threatening Ischemia
Condition
Chronic Limb-Threatening Ischemia
Condition
Diabetic Foot Ulcer
Condition
Infrapopliteal Arterial Occlusive Disease
Intervention (Procedure)
Lower-Extremity Revascularization
Intervention (Genetic)
Donaperminogene Seltoplasmid
Lead sponsor
First Affiliated Hospital of Wenzhou Medical University (class: other)
Collaborator
Beijing Northland Biotech. Co., Ltd. (class: industry)

Record details

Record id
cardio:ct-nct07827521
Content hash
ca2af17859f925ba5620c1a94c18f837e6ba2169bc630ac591537b5bfefa86a8